The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement
BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX) today announced an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.
The agreement between Crown Bioscience, a global technology platform for Oncology, and Cardiovascular and Metabolic Disease, and JAX, a non-profit biomedical research institution and worldwide provider of high-quality research models and services, facilitates the shared objective of both organizations; to accelerate and advance the rate of pre-clinical research and discovery.
As part of the agreement: CrownBio will advance the use of JAX® Mice in client research studies. CrownBio will increase the utilization and improve access of JAX research models, including humanized NSG(TM) and NSG(TM)-SGM3, thus advancing the research and translational efforts of organizations globally.
JAX research scientists will have select access to CrownBio's pre-clinical contract laboratory services, providing JAX scientists with additional resources and facilities in which to continue the search for cures for cancer and other diseases.
"The agreement with JAX heralds a significant step forward for Oncology and Immuno-Oncology pre-clinical research," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. "The utilization of JAX's scientific-leading humanized and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development."
Research teams at JAX, focused on understanding the genetic and biochemical signatures that can be targeted by next-generation precision medicines, will immediately begin leveraging CrownBio's vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
"The Jackson Laboratory's mission is to empower the global biomedical community in our shared quest to improve human health. By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services," stated Auro Nair, Ph.D., President of JAX® Mice, Clinical & Research Services. "Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilizing the world's largest collection of PDX and cell-line models and services from CrownBio."
About Crown Bioscience
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology and cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,900 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.
JAX Contact: Dr. Charles Miller Director of Marketing & Customer Support 207-288-6895 email@example.com Crown Bioscience Media Contact: Gavin Cooper Executive Director Marketing firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressemelding
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressemelding
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31 | Pressemelding
NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999. "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man
Euroloan repays EUR 15 million bond and issues three new bonds to fuel growth21.11.2017 10:32 | Pressemelding
Helsinki, Finland, 2017-11-21 10:32 CET (GLOBE NEWSWIRE) -- Euroloan Group PLC today announced the repayment of a EUR 15 million bond (ISIN code FI4000180351), that had a maturity of 24 months and a coupon of 6%. “We have over ten years of operation built up a level of trust with our investors”, says Tommi Lindfors, Chairman of the Board of Euroloan Group PLC. Euroloan has now issued three new bonds, in total EUR 90 million, to keep up with the rapid growth in its markets. “Although a minor milestone, this small repayment compared to the new bond issues is a concrete example of how much we have grown over the last few years. We intend to grow a lot more in the future.” “All our markets are growing at an unprecedented pace, and future prospects for further growth are even better. In the pay by invoice and lending business, fast growth means that more funding is required to keep up with demand. This is why we have issued these three new bonds to complement our existing facilit
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00 | Pressemelding
CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom